The application for marketing authorization was Emerflu the Agency on 27 April 2007 presented.

The application for marketing authorization was Emerflu the Agency on 27 April 2007 presented. Emerflu received a negative opinion of the Committee for Human Medicinal Products on 19 March 2009 and the time of withdrawal, a decision of the European Commission was pending.

In its official letter the company stated that its decision withdraw the application was based on the CHMP consideration that the data provided do not allow the Committee to conclude on a positive benefit / risk ratio.###, The National Institute of Child Health and Human Development Note: Diabetes and Digestive and Kidney Diseases and the National Institutes of Environmental Health Sciences, all components of the nation Institutes of Health, that new research. Support also came from the U.S. Centers for Disease Control and Prevention.

Other entries from category "fitness":

Random entries